ArticleFrontiers in veterinary science2026
Evaluation of efficacy and pharmacokinetics of novel fluralaner tablet formulation (WellPet™) in dogs.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing use of isoxazolines represents a major trend in the control of ectoparasites in companion animals. WellPet™ (Ourofino Saúde Animal Ltd., Brazil) is a newly developed, highly palatable oral tablet containing fluralaner. This study aimed to characterize the pharmacokinetic profile of this formulation and to evaluate its efficacy against fleas and ticks for up to 45 days following administration. Two complementary studies were conducted. In the pharmacokinetic study, WellPet™ was administered orally to 12 healthy dogs at a dose range of 10 to 22.5 mg/kg, and plasma fluralaner concentrations were measured at predefined time points up to 49 days post-treatment, yielding a peak plasma concentration (Cmax) of 3,763 μg/L, a time to maximum concentration (Tmax) of 2.0 days, an area under the concentration-time curve (AUCtotal) of 53,342.48 μg·day/L, and an elimination half-life (t½) of 17.88 days. In the efficacy study, 12 dogs were randomly allocated into two groups: six animals treated with WellPet™ and six assigned to a negative control group, and were experimentally infested with fleas (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.